Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trialKohei Shitara, Guillermo Ariel Mendez, James Lynam et al.|The Lancet|2018Cited by 1.3k
Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with BevacizumabD. Ngo, Aaron L. Sverdlov, Trent Williams et al.|Journal of Clinical Medicine|2020Cited by 30
Business as unusual: medical oncology services adapt and deliver during <scp>COVID</scp>‐19Avraham Travers, James Lynam, Kim Adler et al.|Internal Medicine Journal|2021Cited by 9
Phase I trial of hypofractionated chemoradiotherapy in the palliative management of esophageal and gastro-esophageal cancerSwetha Sridharan, Jarad Martin, Fiona Day et al.|Radiation Oncology|2022Cited by 7
Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group)Fiona Day, Jarad Martin, Swetha Sridharan et al.|BMC Cancer|2022Cited by 6